Compliance Rate
Compliance Rate
53.0%
Compliant submissions
53
Incompliant submissions
47
Total trials
100
Your Clinical Trials
Showing 25 of 100 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/08/22
End: 01/10/22
Due: 01/11/22
Phase: N/A
Priority: Normal
Start: 01/18/22
End: 01/20/22
Due: 01/21/22
Phase: N/A
Priority: Normal
Start: 01/28/22
End: 01/30/22
Due: 01/31/22
Phase: N/A
Priority: Normal
Start: 02/07/22
End: 02/09/22
Due: 02/10/22
Phase: N/A
Priority: Normal
Start: 02/17/22
End: 02/19/22
Due: 02/20/22
Phase: N/A
Priority: Normal
Start: 02/27/22
End: 03/01/22
Due: 03/02/22
Phase: N/A
Priority: Normal
Start: 03/09/22
End: 03/11/22
Due: 03/12/22
Phase: N/A
Priority: Normal
Start: 03/19/22
End: 03/21/22
Due: 03/22/22
Phase: N/A
Priority: Normal
Start: 03/29/22
End: 03/31/22
Due: 04/01/22
Phase: N/A
Priority: Normal
Start: 04/08/22
End: 04/10/22
Due: 04/11/22
Phase: N/A
Priority: Normal
Start: 06/17/22
End: 06/19/22
Due: 06/20/22
Phase: N/A
Priority: Normal
Start: 07/07/22
End: 07/09/22
Due: 07/10/22
Phase: N/A
Priority: Normal
Start: 01/03/23
End: 01/05/23
Due: 01/06/23
Phase: N/A
Priority: Normal
Start: 02/27/24
End: 02/29/24
Due: 03/01/24
Phase: N/A
Priority: Normal
Start: 01/31/93
End: 01/31/98
Due: 01/31/99
Phase: N/A
Priority: Normal
Start: -
End: 08/31/04
Due: 08/31/05
Phase: N/A
Priority: Normal
Start: 09/30/87
End: 10/31/00
Due: 10/31/01
Phase: N/A
Priority: Normal
Start: -
End: 01/31/05
Due: 01/31/06
Phase: N/A
Priority: Normal
Start: -
End: 11/30/06
Due: 11/30/07
Phase: N/A
Priority: Normal
Start: -
End: 12/31/88
Due: 12/31/89
Phase: N/A
Priority: Normal
Start: 08/31/86
End: 03/31/98
Due: 03/31/99
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/31/94
End: -
Due: -
Phase: N/A
Priority: Normal
Start: -
End: 06/30/02
Due: 06/30/03
Phase: N/A
Priority: Normal
Start: 06/30/93
End: 04/30/99
Due: 04/30/00
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study 7 | NCT00000006 | Organization 7 | user7@example.com | Incompliant | 2022-01-08 | 2022-01-10 | 2022-01-11 | 2025-07-01 | Admin | 2025-07-01 |
| Study 17 | NCT00000016 | Organization 17 | user7@example.com | Incompliant | 2022-01-18 | 2022-01-20 | 2022-01-21 | 2025-07-01 | Admin | 2025-07-01 |
| Study 27 | NCT00000026 | Organization 27 | user7@example.com | Compliant | 2022-01-28 | 2022-01-30 | 2022-01-31 | 2025-07-01 | Admin | 2025-07-01 |
| Study 37 | NCT00000036 | Organization 37 | user7@example.com | Compliant | 2022-02-07 | 2022-02-09 | 2022-02-10 | 2025-07-01 | Admin | 2025-07-01 |
| Study 47 | NCT00000046 | Organization 47 | user7@example.com | Compliant | 2022-02-17 | 2022-02-19 | 2022-02-20 | 2025-07-01 | Admin | 2025-07-01 |
| Study 57 | NCT00000056 | Organization 57 | user7@example.com | Compliant | 2022-02-27 | 2022-03-01 | 2022-03-02 | 2025-07-01 | Admin | 2025-07-01 |
| Study 67 | NCT00000066 | Organization 67 | user7@example.com | Incompliant | 2022-03-09 | 2022-03-11 | 2022-03-12 | 2025-07-01 | Admin | 2025-07-01 |
| Study 77 | NCT00000076 | Organization 77 | user7@example.com | Compliant | 2022-03-19 | 2022-03-21 | 2022-03-22 | 2025-07-01 | Admin | 2025-07-01 |
| Study 87 | NCT00000086 | Organization 87 | user7@example.com | Incompliant | 2022-03-29 | 2022-03-31 | 2022-04-01 | 2025-07-01 | Admin | 2025-07-01 |
| Study 97 | NCT00000096 | Organization 97 | user7@example.com | Incompliant | 2022-04-08 | 2022-04-10 | 2022-04-11 | 2025-07-01 | Admin | 2025-07-01 |
| Study 167 | NCT00000166 | Organization 67 | user7@example.com | Compliant | 2022-06-17 | 2022-06-19 | 2022-06-20 | 2025-07-01 | Admin | 2025-07-01 |
| Study 187 | NCT00000186 | Organization 87 | user7@example.com | Incompliant | 2022-07-07 | 2022-07-09 | 2022-07-10 | 2025-07-01 | Admin | 2025-07-01 |
| Study 367 | NCT00000366 | Organization 67 | user7@example.com | Compliant | 2023-01-03 | 2023-01-05 | 2023-01-06 | 2025-07-01 | Admin | 2025-07-01 |
| Study 787 | NCT00000786 | Organization 87 | user7@example.com | Compliant | 2024-02-27 | 2024-02-29 | 2024-03-01 | 2025-07-01 | Admin | 2025-07-01 |
| Neurobiology of Opioid Dependence: 5 - 5 | NCT00000196 | Yale University | user7@example.com | Compliant | 1993-01-31 | 1998-01-31 | 1999-01-31 | 2025-07-01 | - | 2025-07-14 |
| A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood | NCT00000916 | National Institute of Allergy and Infectious Diseases (NIAID) | user7@example.com | Compliant | - | 2004-08-31 | 2005-08-31 | 2025-07-01 | - | 2025-07-14 |
| Postmenopausal Estrogen/Progestin Interventions (PEPI) | NCT00000466 | National Heart, Lung, and Blood Institute (NHLBI) | user7@example.com | Incompliant | 1987-09-30 | 2000-10-31 | 2001-10-31 | 2025-07-01 | - | 2025-07-14 |
| Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1 | NCT00000216 | Yale University | user7@example.com | Incompliant | - | 2005-01-31 | 2006-01-31 | 2025-07-01 | - | 2025-07-14 |
| Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children | NCT00000876 | National Institute of Allergy and Infectious Diseases (NIAID) | user7@example.com | Compliant | - | 2006-11-30 | 2007-11-30 | 2025-07-01 | - | 2025-07-14 |
| Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine | NCT00000706 | National Institute of Allergy and Infectious Diseases (NIAID) | user7@example.com | Compliant | - | 1988-12-31 | 1989-12-31 | 2025-07-01 | - | 2025-07-14 |
| Cardiac Arrhythmia Suppression Trial (CAST) | NCT00000526 | National Heart, Lung, and Blood Institute (NHLBI) | user7@example.com | Incompliant | 1986-08-31 | 1998-03-31 | 1999-03-31 | 2025-07-01 | - | 2025-07-14 |
| Cognitive Correlates of Substance Abuse - 11 | NCT00000346 | National Institute on Drug Abuse (NIDA) | user7@example.com | Compliant | - | - | - | 2025-07-01 | - | 2025-07-14 |
| Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) | NCT00000126 | National Eye Institute (NEI) | user7@example.com | Incompliant | 1994-10-31 | - | - | 2025-07-01 | - | 2025-07-14 |
| Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3 | NCT00000756 | National Institute of Allergy and Infectious Diseases (NIAID) | user7@example.com | Compliant | - | 2002-06-30 | 2003-06-30 | 2025-07-01 | - | 2025-07-14 |
| Inhaled Beclomethasone to Prevent Chronic Lung Disease | NCT00000576 | National Heart, Lung, and Blood Institute (NHLBI) | user7@example.com | Compliant | 1993-06-30 | 1999-04-30 | 2000-04-30 | 2025-07-01 | - | 2025-07-14 |